Table 2.
Characteristic | POWIR (N=35) Mean (SD) |
FLEX (N=36) Mean (SD) |
p value* |
---|---|---|---|
Age (years) | 46.5 (5.0) | 46.4 (4.9) | 0.90 |
Comorbidity index | 1.9 (1.6) | 2.1 (1.6) | 0.66 |
Body mass index (kg/m2) | 27.0 (5.4) | 25.8 (4.6) | 0.32 |
Spine T-score | −0.5 (1.1) | −0.4 (1.0) | 0.86 |
Femoral neck T-score | −0.4 (0.9) | −0.5 (0.9) | 0.46 |
FSH (IU) | 79.5 (45.0) | 62.9 (33.9) | 0.09 |
Estradiol (pg/ml) | 15.0 (20.1) | 35.0 (79.3) | 0.16 |
Time since diagnosis (months) | 30.1 (18.3) | 30.1 (15.5) | 0.99 |
Time since menopause (months) | 24.1 (17.4) | 26.1 (15.4) | 0.61 |
Stage I (%) | 22.9 % | 33.3 % | 0.41** |
Stage II (%) | 65.7 % | 50.0 % | |
Stage IIIa (%) | 11.4 % | 16.7 % | |
Received radiation therapy (%) | 62.9 % | 61.1 % | 0.88 |
Currently taking AI (%) | 40.0 % | 30.6 % | 0.70** |
Currently taking SERM (%) | 37.1 % | 44.4 % |
Data presented as mean (SD) for continuous data or percentage of sample for categorical data
AI aromatase inhibitor; SERM selective estrogen receptor modulator
p value from unpaired t test for continuous data and from chi-squares test for categorical data;
p value for differences in the distribution of cancer stage (I, II, or IIIa) or adjuvant hormone therapy (none, AI, and SERM) between study groups